–   On primary efficacy and key secondary endpoints, TransCon hGH demonstrated statistically significant reduction from baseline in trunk fat and increase in total body lean mass at Week 38 compared to placebo –   TransCon hGH was generally safe and well tolerated, similar to daily hGH, with no discontinuations related to study drug –   Exploratory post-hoc analysis suggests the same treatment effects on target tissues as daily hGH COPENHAGEN, Denmark, Dec.

–在主要疗效和关键次要终点方面，与安慰剂相比，TransCon hGH在第38周时躯干脂肪从基线水平显着降低，全身瘦体重增加–TransCon hGH通常安全且耐受性良好，与每日hGH相似，没有与研究药物相关的停药-探索性事后分析表明，对靶组织的治疗效果与丹麦哥本哈根每日hGH相同。

19, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced positive topline results from foresiGHt, its Phase 3 randomized, parallel-arm, placebo-controlled (double-blind) and active-controlled (open-label) trial to compare the efficacy and safety of TransCon hGH (lonapegsomatropin) with placebo and daily hGH (human growth hormone, somatropin) in adults with growth hormone deficiency (GHD).

2023年19月19日（环球通讯社）--Ascendis Pharma A/S（纳斯达克股票代码：ASND）今天宣布，其第三阶段随机平行分支foresiGHt取得了积极的结果，安慰剂对照（双盲）和主动对照（开放标签）试验，比较TransCon hGH（lonapegsomatropin）与安慰剂和每日hGH（人类生长激素，生长激素）在生长激素缺乏症（GHD）成人中的疗效和安全性。

The foresiGHt Trial evaluated 259 adults with GHD aged 23 to 80 years old, randomized 1:1:1, titrated to receive a target fixed dose of TransCon hGH, placebo, or daily hGH based on age and oral estrogen intake with approximately equivalent hGH mg/week for TransCon hGH and daily hGH. TransCon hGH demonstrated superiority on its primary efficacy endpoint at Week 38: Change from baseline in trunk percent fat as measured by dual x-ray absorptiometry (TransCon hGH -1.67% vs.

foresiGHt试验评估了259名年龄在23至80岁之间的GHD成年人，随机分为1:1:1，根据年龄和口服雌激素摄入量，滴定接受目标固定剂量的TransCon hGH，安慰剂或每日hGH，TransCon hGH和每日hGH的hGH毫克/周。TransCon hGH在第38周的主要疗效终点表现出优越性：通过双x射线吸收测定法测量的躯干脂肪百分比从基线变化（TransCon hGH-1.67%vs。

placebo +0.37%, LS mean difference = -2.04%, p < 0.0001) TransCon hGH demonstrated superiority on its key secondary efficacy endpoints at Week 38: Change from baseline in total body lean mass (TransCon hGH +1.60 kg vs placebo -0.10 kg, LS mean difference = 1.70 kg, p < 0.0001)Change from baseline in trunk fat mass (TransCon hGH -0.48 kg vs placebo +0.22 kg, LS mean difference = -0.70 kg, p = 0.0053) Exploratory post-hoc analysis at Week 38 de.

安慰剂+0.37%，LS平均差异=-2.04%，p<0.0001）TransCon hGH在第38周表现出优于其关键次要疗效终点：在第38周，全身瘦肉量（TransCon hGH+1.60 kg vs安慰剂-0.10 kg，LS平均差异=1.70 kg，p<0.0001）从基线变化（TransCon hGH-0.48 kg vs安慰剂+0.22 kg，LS平均差异=-0.70 kg，p=0.0053）探索性事后分析德国。